Clinical research plays a vital role in the war on cancer. Through research we discover new and better ways to fight this disease, improve the quality of life for patients, and ultimately one day, to prevent cancer. Research studies, also called clinical trials or protocols, help develop better treatments to improve survival, understand how cancer grows and manage side effects of treatment to improve quality of life.
Pearlman offers clinical trials sponsored by the National Cancer Institute as well as pharmaceutical companies.
There’s been a lot of interest in recent years to refine the strategy for treating chronic or life-threatening diseases using more precise means of targeting the driver of the illness. In cancer, we’re examining the molecular environment and genetic code of tumors to identify abnormalities that can be eliminated or altered by a drug. Pearlman Cancer Center is opening a series of trials through the National Cancer Institute’s Precision Medicine Initiative that will offer patients with advanced cancers an opportunity to benefit from this innovative strategy. The Lung-MAP Study is the first of these trials, and it consists of several sub-studies within the larger umbrella trial. New sub-studies will be added as new potential targets are identified for exploration in squamous cell lung cancer. ALCHEMIST will be the next trial to open, followed by NCI-MATCH. This is an exciting time in cancer research as we discover how to use the unique biology of the patient’s tumor to fight the cancer.
Clinical Trials: Protocols Available by Disease Site
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
(ALCHEMIST) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial. A screening trial for A081105 and E4512.
(An ALCHEMIST sub-study) A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(An ALCHEMIST sub-study) Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Lung Cancer (NSCLC)
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
The following disease sites have no studies available at this time: Gallbladder, Genitourinary, GIST, Head and Neck, Leukemia, Lymphoma, Melanoma, Myeloma, Pancreas and Prostate.